Is VTE Prophylaxis Necessary on Discharge for Patients Undergoing Adrenalectomy for Cushing Syndrome?

Cushing syndrome VTE thromboprophylaxis adrenalectomy hypercoaguable

Journal

Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 28 08 2018
accepted: 07 12 2018
entrez: 18 1 2019
pubmed: 18 1 2019
medline: 18 1 2019
Statut: epublish

Résumé

Patients with Cushing syndrome (CS) have an increased risk for venous thromboembolism (VTE). However, it is unclear whether patients undergoing adrenalectomy for CS are at increased risk for postoperative VTE. The aim of this study was to determine the rate of postoperative VTE in patients undergoing adrenalectomy for CS. A retrospective analysis of patients in the American College of Surgeons National Surgical Quality Improvement Program database who underwent adrenalectomy from 2005 to 2016 was performed. We compared the clinical characteristics and 30-day postoperative VTE occurrence in patients with and without CS. A total of 4217 patients were analyzed; 2607 (61.8%) were female and 310 (7.4%) had CS. The overall prevalence of postoperative VTE was 1.0% (n = 45). The rates of VTE were higher in patients with CS (2.6% vs 0.9%; The prevalence of postoperative VTE was increased in patients undergoing adrenalectomy for CS. In patients with CS undergoing adrenalectomy, VTE prophylaxis for 28 days should be considered upon discharge.

Sections du résumé

BACKGROUND BACKGROUND
Patients with Cushing syndrome (CS) have an increased risk for venous thromboembolism (VTE). However, it is unclear whether patients undergoing adrenalectomy for CS are at increased risk for postoperative VTE. The aim of this study was to determine the rate of postoperative VTE in patients undergoing adrenalectomy for CS.
METHODS METHODS
A retrospective analysis of patients in the American College of Surgeons National Surgical Quality Improvement Program database who underwent adrenalectomy from 2005 to 2016 was performed. We compared the clinical characteristics and 30-day postoperative VTE occurrence in patients with and without CS.
RESULTS RESULTS
A total of 4217 patients were analyzed; 2607 (61.8%) were female and 310 (7.4%) had CS. The overall prevalence of postoperative VTE was 1.0% (n = 45). The rates of VTE were higher in patients with CS (2.6% vs 0.9%;
CONCLUSIONS CONCLUSIONS
The prevalence of postoperative VTE was increased in patients undergoing adrenalectomy for CS. In patients with CS undergoing adrenalectomy, VTE prophylaxis for 28 days should be considered upon discharge.

Identifiants

pubmed: 30652131
doi: 10.1210/js.2018-00278
pii: js_201800278
pmc: PMC6330172
doi:

Types de publication

Journal Article

Langues

eng

Pagination

304-313

Références

Am J Clin Pathol. 2000 Jan;113(1):123-7
pubmed: 10631865
J Clin Endocrinol Metab. 2002 Aug;87(8):3662-6
pubmed: 12161492
J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602
pubmed: 14671138
Chest. 2008 Jun;133(6 Suppl):381S-453S
pubmed: 18574271
Endocrine. 2009 Aug;36(1):70-4
pubmed: 19381886
J Clin Endocrinol Metab. 2009 Aug;94(8):2743-50
pubmed: 19454584
Ann Surg. 2009 Sep;250(3):363-76
pubmed: 19644350
Eur J Endocrinol. 2010 Nov;163(5):783-91
pubmed: 20696792
Surgery. 2011 Nov;150(5):943-9
pubmed: 21875734
J Clin Endocrinol Metab. 2011 Nov;96(11):3525-32
pubmed: 21880802
Chest. 2012 Feb;141(2 Suppl):e227S-e277S
pubmed: 22315263
Pituitary. 2013 Jun;16(2):175-81
pubmed: 22585010
Clin Endocrinol (Oxf). 2013 Apr;78(4):481-8
pubmed: 23134530
Semin Thromb Hemost. 2013 Jul;39(5):489-95
pubmed: 23633192
J Clin Endocrinol Metab. 2013 Oct;98(10):3939-48
pubmed: 23956347
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S699-706
pubmed: 25968622
Eur J Endocrinol. 2015 Oct;173(4):M11-21
pubmed: 25971647
J Thromb Thrombolysis. 2016 Apr;41(3):475-81
pubmed: 25982217
Endocrine. 2016 May;52(2):322-32
pubmed: 26113424
Urology. 2016 Apr;90:62-8
pubmed: 26743396
Cochrane Database Syst Rev. 2016 Mar 30;3:CD004179
pubmed: 27027384
Horm Metab Res. 2017 May;49(5):365-371
pubmed: 28226363
Eur J Endocrinol. 2018 Apr;178(4):399-409
pubmed: 29440375
Clin Endocrinol (Oxf). 1994 Apr;40(4):479-84
pubmed: 8187313
Ann Surg. 1998 Oct;228(4):491-507
pubmed: 9790339

Auteurs

Bruna Babic (B)

Department of Surgery, New York Presbyterian-Queens, Flushing, New York.

Amory De Roulet (A)

Department of Surgery, New York Presbyterian-Queens, Flushing, New York.

Anita Volpe (A)

Department of Surgery, New York Presbyterian-Queens, Flushing, New York.

Naris Nilubol (N)

Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Classifications MeSH